A report published in January 2025 by the US Office of Inspector General identified significant flaws in accelerated approval processes for three drugs (Biogens Aduhelm/aducanumab, Sareptas Exondys/eteplirsen, and Covis Pharma Groups Makena/hydroxyprogesterone caproate), raising questions over the effectiveness and consistency of the fast track pathway
[DOI] [PubMed] [Google Scholar] 81.Astrup A, Rssner S, Van Gaal L, et al
The reach of GLP-1 drugs is now widening in ways its inventors couldnt have imagined, Couzin-Frankel wrote
Weight loss through diet or bariatric surgery has also been used to treat OSA, but until now, weve lacked effective medications to achieve substantial weight loss
Slight elevations are not always clinically significant
Step 7: If anything seems off, stop